Financial News with AI Impact Scores

Infosys Shares Halted On Circuit Breaker To The Upside, Stock Now Up 38.79%

MHRA Approves Lenacapavir For The Prevention Of Sexually Transmitted HIV-1 Infection

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lenacapavir for the prevention of sexually transmitted HIV-1 infection. This approval is a significant milestone for Gilead Sciences (GILD), as it expands their portfolio in HIV prevention. The approval is expected to impact the market positively, potentially increasing GILD's revenue from HIV-related treatments.

RBC Capital Maintains Outperform on Huntington Bancshares, Raises Price Target to $20

RBC Capital analyst Jon G. Arfstrom has maintained an 'Outperform' rating on Huntington Bancshares (NASDAQ: HBAN) and raised the price target from $19 to $20. This adjustment reflects a positive outlook for the company in the market.

Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results

On Friday, the Dow Jones index rose by over 200 points, closing up 0.49% at 48,188.36, while the NASDAQ and S&P 500 also saw gains of 1.03% and 0.73%, respectively. Conagra Brands Inc (NYSE:CAG) shares fell more than 4% after reporting Q2 earnings of 45 cents per share, which beat the analyst consensus estimate of 44 cents, but sales of $2.979 billion missed the expected $2.986 billion. In commodities, oil increased by 1% to $56.47, while gold decreased by 0.2% to $4,365.60.

Carnival shares are trading higher after the company announced better-than-expected Q4 adjusted EPS results and issuedFY26 adjusted EPS guidance above estimates.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

Canaccord Genuity analyst John Newman has maintained a 'Buy' rating on Atara Biotherapeutics (NASDAQ: ATRA) and raised the price target from $17 to $25. This adjustment reflects a positive outlook on the company's performance.

Vuzix Extends Multi-Year Collaboration With RTX's Collins Aerospace For Advanced Waveguide AR Display Systems; Production Approved And Delivered For Deployment Across Multiple U.S. DoD Programs

Vuzix Corporation (NASDAQ: VUZI) has extended its multi-year collaboration with Collins Aerospace, a business unit of RTX, for the development of advanced waveguide AR display systems for the U.S. Department of Defense. The partnership has led to the production approval and delivery of a waveguide-based display engine, with low-rate initial production set to begin soon and full-rate production anticipated to start in 2026. This collaboration positions Vuzix as a key player in U.S. defense manufacturing, with initial hardware deliveries expected in Q1 2026.

Citron Research Posts On X "Citron adds to $CCCX. Based on technology, valuation, and national-security relevance, $CCCX should trade at least $27 if $RGTI is valued at today's price @DivesTech laid out his 2026 outlook, including a scenario where the Trump Administration makes a strategic investment in a U.S. quantum company for national security. If that happens, one company stands out head-and-shoulders above the rest..."

Citron Research has expressed a bullish outlook on the stock $CCCX, suggesting it should trade at a minimum of $27 based on its technology, valuation, and national-security relevance. This assessment comes in light of a potential strategic investment by the Trump Administration in a U.S. quantum company, which could elevate $CCCX's standing in the market. The commentary highlights the company's significance compared to others in the sector.

FDA Says On Dec 18, Said It Got Postmarketing Safety Data On Thromboembolic Events, Including Serious & Fatal Outcomes, In Patients Treated With Andexxa; Astrazeneca Submitted Request To Voluntarily Withdraw BLA For Andexxa For Commercial Reasons; Based On Available Data, FDA Considers Risks Of Andexxa To Outweigh Its Benefits; Andexxa Will No Longer Be Manufactured For Or Sold In U.S. By Astrazeneca After Dec 22, 2025

The FDA announced on December 18 that it received postmarketing safety data indicating thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa. AstraZeneca has submitted a request to voluntarily withdraw its Biologics License Application (BLA) for Andexxa due to commercial reasons, as the FDA considers the risks of Andexxa to outweigh its benefits. Consequently, Andexxa will no longer be manufactured or sold in the U.S. by AstraZeneca after December 22, 2025.

ConAgra Flags Rising Costs From Tariffs, Keeps Cautious Outlook

ConAgra Brands, Inc. reported second-quarter adjusted earnings per share of 45 cents, exceeding analyst expectations of 44 cents, but missed revenue estimates with quarterly sales of $2.979 billion compared to the expected $2.986 billion. The company reaffirmed its fiscal 2026 adjusted EPS guidance of $1.70 to $1.85 and projected organic net sales to change between a 1% decline and flat growth. ConAgra anticipates continued cost-of-goods-sold inflation, estimating a total inflation of about 7% for fiscal 2026, largely due to U.S. tariffs, which could increase costs by approximately 3%.